

## Original Research Article

# Hepatoprotective activity of *Bixa Orellana* plant extract against hepatotoxicity in Rodent

### Abstract

**Introduction:** Hepatotoxicity, or liver damage, can result from exposure to toxic substances such as medications, chemicals, alcohol, and environmental pollutants, affecting approximately 1.5 billion people worldwide. Although synthetic drugs offer therapeutic benefits, they often come with side effects. Medicinal plants may offer a viable alternative. This study examines *Bixa Orellana*, a plant known for its antioxidant properties, to evaluate its potential protective effects on the liver.

**Method:** The study used 45 Swiss Albino rats, divided into 9 groups. Hepatotoxicity was induced using carbon tetrachloride (CCl<sub>4</sub>). Group 1 was negative control group where only normal foods were given. Groups 2 to 6 were exposed to CCl<sub>4</sub>, while Groups 7 through 9 received low, medium, and high doses of *Bixa Orellana* extract, respectively. The treatments lasted for 42 days, after which the rats were sacrificed for analysis.

**Results:** Liver function tests (SGPT and SGOT) showed significant improvements, particularly with medium (600mg/kg) and high (1200mg/kg) doses of the extract. Kidney function tests revealed promising results for creatinine levels with low (300mg/kg) and medium (600mg/kg) doses, although urea levels did not change significantly. The lipid profile analysis indicated substantial benefits at high (1200mg/kg) doses, with improvements in HDL, LDL, and cholesterol levels, though triglyceride levels did not show significant changes.

**Conclusion:** The findings suggest that *Bixa Orellana* has considerable hepatoprotective effects. Further studies are needed to explore its potential as a therapeutic agent for liver protection and to develop detailed reports on its efficacy.

Keywords: Bixa Orellana plant, Hepatotoxicity, liver damage

## 1.Introduction

The liver, the largest and most intricate internal organ in the human body, makes up approximately 2-3% of an adult's body weight. Chronic Liver Diseases (CLD) affect an estimated 1.5 billion people globally, with a notable 31% increase in the United States among individuals aged 45-64 years [1]. The liver is especially prone to cellular damage from increased Reactive Oxygen Species (ROS) such as OH, H<sub>2</sub>O<sub>2</sub>, and O<sub>2</sub>, which can result from excessive alcohol consumption, drug abuse, exposure to certain toxins, or viral and parasitic infections [2]. L-glutathione, composed of L-cysteine, glycine, and L-glutamate, is a low molecular weight, water-soluble tripeptide known for its role as a free-radical scavenger and is often taken as an oral supplement alongside ascorbic acid. This combination is valued for its detoxifying, antioxidant properties and its ability to bolster the immune system [3-6]. However, it may cause digestive issues, stomach cramps, bloating, diarrhea, breathing difficulties due to bronchoconstriction, and allergic reactions such as dermatitis.

Plants are a vital source of new drug discoveries and synthesis due to their rich diversity of naturally occurring therapeutic chemicals. These plant-derived compounds can serve as safer, more effective alternatives to current medicines or be further researched for their therapeutic potential. Scientists in the field of medicinal plants believe that unique chemical compounds produced by these plants may offer significant therapeutic benefits. Thus, there is a continuous search for alternative or plant-based herbal medications to treat various ailments. Medicinal plants are known for their wide range of pharmacological and therapeutic effects, attributable to their numerous chemical constituents such as phenols, alkaloids, terpenoids, saponins, glycosides, tannins, flavonoids, resins, polysaccharides, plant lipids, and essential oils [7-9]. The desired therapeutic effect can be achieved by manipulating the concentration of these chemical components, potentially through genetic manipulation of the plants. For example, reverse genetics can enhance the biosynthesis of secondary metabolites like alkaloids [10-11].

Hepatoprotective properties have been observed in *Acacia mellifera*, *Adansonia digitata* L, and *Cannabis sativa* L [12-14].

*Bixa Orellana*, is a tree from the Bixaceae family, native to Central America [15]. It contains various compounds, including bixin norbixin, isobixin, beta-carotene, cryptoxanthin, lutein, zeaxanthin, orellin, bixein, bixol, crocetin, ishwarane, ellagic acid, salicylic acid, threonine, tomentosic acid, tryptophan, and phenylalanine [16-17]. Recently, natural compounds from plants have drawn significant interest due to their diverse pharmacological properties, including antioxidant and hepatoprotective activities [18]. The *Bixa Orellana* plant contains various compounds that may protect the liver. Notably, bixin, a carotenoid pigment in the seeds, has been shown to have antioxidant properties that help shield the liver from damage. Other compounds such as norbixin also play a role in the plant's liver-protective effects [19]. This study aims to explore the hepatoprotective potential of *Bixa Orellana* in a Carbon tetrachloride (CCl<sub>4</sub>) induced experimental rat model, as well as assess any potential adverse effects on the liver, in the pursuit of a safer, more affordable, and more effective drug.

## **2. Materials and Methods:**

### **2.1. Plant Collection and Extract Preparation**

Fruits of *Bixa Orellana* were procured from a local market in Dhaka and authenticated by the Department of Pharmacy at the University of Dhaka. The fresh fruits were air-dried and meticulously crushed into a fine powder. This powder was then subjected to extraction with 50% ethanol over a span of 15 days, with filtration conducted every three days. The resulting extract was concentrated using a rotary evaporator under low temperature and pressure conditions. The final crude residue was prepared for subsequent pharmacological testing.

### **2.2. Drugs and Chemicals**

Carbon tetrachloride (CCl<sub>4</sub>), a well-known hepatotoxicity causing chemical, was purchased from the Sigma firm in the United States. The typical anti-oxidant medication Silymarin was purchased as Livasil 140 mg from Incepta Pharmaceuticals Ltd.

### **2.3. Experimental Animal Procurement, Nursing, and Grouping**

45 male rats, each weighing between 120 and 150 grams, were obtained from Jahangirnagar University in Savar, Dhaka. They were housed individually in a climate-controlled environment (temperature  $25\pm 3^{\circ}\text{C}$ , relative humidity  $55\pm 5\%$ , and a 12-hour light/dark cycle) at the Institute of Nutrition & Food Science (INFS) at the University of Dhaka. The rats were provided with standard food and clean water. They were kept in this environment for at least one week before the start of the research to allow for acclimatization.

#### 2.4. Animal Model Sample Size Detection

The 45 rats were randomly divided into 9 groups, with each group consisting of 5 rats. The random assignment was intended to enhance the validity of the study. Daily observations were conducted during the mating season. Both positive and negative control groups were included in the study.

#### 2.5. Dose Selection and Route of Administration for Respective Study

Carbon tetrachloride ( $\text{CCl}_4$ ) is commonly used in laboratories to model various liver diseases, both acute and chronic. The metabolite trichloromethyl free radical ( $\text{CCl}_3$ ), produced by the CYP2E1 isozyme from  $\text{CCl}_4$ , interacts with cellular lipids and proteins to form trichloromethyl peroxy radical, which causes lipid peroxidation and lobular necrosis more rapidly than trichloromethyl free radical. A single oral dose of  $\text{CCl}_4$  mixed with olive oil in a 1:1 ratio (3 ml/kg of rat body weight) induced liver damage in all groups except the normal control group. *Bixa Orellana* extracts were administered orally in various doses to the animals with hepatic injury as a post-treatment.

#### 2.6. Evaluation of Hepato–Protective Activity

For this experiment, 45 rats were randomly picked and equally divided into 9 groups (Table 1).

**Table 1 : Application of treatment efficacy**

| Group Number | Group Specification | Treatment species    | Dose treatment species (mg/kg) |
|--------------|---------------------|----------------------|--------------------------------|
| 1            | Negative control    | Physiological saline | 10 ml/kg                       |

|   |                                       |                      |      |
|---|---------------------------------------|----------------------|------|
| 2 | CCl <sub>4</sub>                      | N/A                  | N/A  |
| 3 | CCl <sub>4</sub> + S <sub>80</sub>    | Silymarin            | 80   |
| 4 | CCl <sub>4</sub> + BO <sub>300</sub>  | <i>Bixa Orellana</i> | 300  |
| 5 | CCl <sub>4</sub> + BO <sub>600</sub>  | <i>Bixa Orellana</i> | 600  |
| 6 | CCl <sub>4</sub> + BO <sub>1200</sub> | <i>Bixa Orellana</i> | 1200 |
| 7 | BO <sub>300</sub>                     | <i>Bixa Orellana</i> | 300  |
| 8 | BO <sub>600</sub>                     | <i>Bixa Orellana</i> | 600  |
| 9 | BO <sub>1200</sub>                    | <i>Bixa Orellana</i> | 1200 |

In our experimental design, Group 1 served as the negative control, receiving only regular food, establishing a baseline for comparison. Group 2 acted as the disease control group, where CCl<sub>4</sub> was administered to induce disease, without any subsequent treatment, to provide a comparative basis for the effects of the treatments of group 4, 5 and 6 in the "One-way ANOVA " test . Groups 4, 5, and 6 were treated with varying doses of the drug: low (300 mg/kg), medium (600 mg/kg), and high (1200 mg/kg), respectively.

In contrast, in group 7, 8, and 9 were given the same low (300 mg/kg), medium (600 mg/kg), and high (1200 mg/kg) doses of the drug respectively without disease induction. This approach was designed to identify any potential side effects of the drug in the absence of the disease.

## 2.7 Statistical Analysis

All numerical data were recorded and analyzed using MS Excel. Descriptive statistics were applied to the collected data, and the results were reported as mean ± SD. To assess statistical significance, the "One-way ANOVA test" in SPSS 16 software was used to interpret inter-group variability for various biological factors. Results were considered statistically significant if the p-value was less than 0.05 (p<0.05).

### 3.Results and Discussion

**Table 2 : Liver function test**

| Group                                 | SGPT           | SGOT          |
|---------------------------------------|----------------|---------------|
| Negative control                      | 35.29 ± 4.27   | 46.28 ± 1.89  |
| CCl <sub>4</sub>                      | 110.47 ± 11.60 | 110.10 ± 7.29 |
| CCl <sub>4</sub> + S <sub>10</sub>    | 52.57 ± 6.93   | 67.25 ± 8.85  |
| CCl <sub>4</sub> + BO <sub>300</sub>  | 105.67 ± 9.97  | 107.29 ± 8.89 |
| CCl <sub>4</sub> + BO <sub>600</sub>  | 101.23 ± 8.88* | 103 ± 7.59    |
| CCl <sub>4</sub> + BO <sub>1200</sub> | 97.75 ± 10.52* | 98.52 ± 6.01  |
| BO <sub>300</sub>                     | 37.81 ± 5.67   | 43.46 ± 2.87  |
| BO <sub>600</sub>                     | 35.89 ± 7.86   | 47.37 ± 5.29  |
| BO <sub>1200</sub>                    | 39.29 ± 8.75   | 42.74 ± 8.29  |

**Table 3 : Kidney function test**

| Goup                                  | Creatinine   | Urea           |
|---------------------------------------|--------------|----------------|
| Negative control                      | 0.57 ± 0.011 | 38.46 ± 8.24   |
| CCl <sub>4</sub>                      | 2.86 ± 0.95  | 105.52 ± 13.23 |
| CCl <sub>4</sub> + S <sub>10</sub>    | 1.25 ± 0.87  | 52.24 ± 42.24  |
| CCl <sub>4</sub> + BO <sub>300</sub>  | 2.50 ± 0.93* | 101.70 ± 18.58 |
| CCl <sub>4</sub> + BO <sub>600</sub>  | 2.23 ± 0.86* | 96.29 ± 5.93   |
| CCl <sub>4</sub> + BO <sub>1200</sub> | 1.89 ± 0.93  | 91.06 ± 4.20   |
| BO <sub>300</sub>                     | 0.63 ± 0.13  | 39.75 ± 6.50   |
| BO <sub>600</sub>                     | 0.75 ± 0.45  | 35.20 ± 5.39   |
| BO <sub>1200</sub>                    | 0.57 ± 0.48  | 38.20 ± 6.08   |

**Table 4 : Lipid profile**

| Group                                 | Total cholesterol | HDL           | LDL            | Triglyceride   |
|---------------------------------------|-------------------|---------------|----------------|----------------|
| Negative control                      | 107.34 ± 6.24     | 88.24 ± 2.82  | 46.25 ± 4.25   | 55.39 ± 4.67   |
| CCl <sub>4</sub>                      | 203.34 ± 14.21    | 47.90 ± 6.50  | 150.29 ± 6.36  | 107.54 ± 10.30 |
| CCl <sub>4</sub> + S <sub>10</sub>    | 151.23 ± 10.39    | 65.29 ± 5.55  | 77.79 ± 6.39   | 69.96 ± 8.62   |
| CCl <sub>4</sub> + BO <sub>300</sub>  | 200.04 ± 12.47    | 48.29 ± 0.29  | 147.50 ± 8.37  | 105.26 ± 8.67  |
| CCl <sub>4</sub> + BO <sub>600</sub>  | 196.93 ± 13.39    | 51.29 ± 5.29  | 143.90 ± 6.29  | 104.22 ± 7.62  |
| CCl <sub>4</sub> + BO <sub>1200</sub> | 199.96 ± 13.26*   | 54.48 ± 6.18* | 140.19 ± 7.53* | 101.39 ± 5.29  |
| BO <sub>300</sub>                     | 103.52 ± 6.39     | 86.26 ± 3.38  | 48.19 ± 5.30   | 52.52 ± 5.19   |
| BO <sub>600</sub>                     | 109.39 ± 8.24     | 84.52 ± 2.93  | 45.53 ± 6.12   | 54.39 ± 4.18   |
| BO <sub>1200</sub>                    | 105.39 ± 7.29     | 85.80 ± 3.45  | 48.59 ± 5.73   | 54.18 ± 2.20   |

Assessing the hepatoprotective properties of plants typically involves various methods to quantify specific biochemical markers, as there is no single universal paradigm for accurately and qualitatively measuring hepatoprotective activity. The liver is more susceptible to toxic damage than other organs, making drug-induced liver injury a significant health concern, especially with the extensive use of certain medications. Research on the mechanisms of drug-induced liver injury is crucial for its treatment and prevention. Given the lack of reliable hepatoprotective drugs in contemporary medicine, herbal treatments for liver disorders have gained popularity. Numerous herbs notably as plant Silymarin demonstrated potential effectiveness in treating liver cirrhosis.[20-21]

### 3.1 Liver function test

### **3.1.1 SGPT**

Carbon tetrachloride (CCl<sub>4</sub>) increases serum glutamate pyruvate transaminase (SGPT) levels by damaging the liver. Its metabolism generates reactive free radicals that cause oxidative stress and harm liver cells. This damage disrupts cell membranes, allowing SGPT to leak into the blood, which signals liver cell injury and dysfunction [22]. In this study group 4,5 and 6 SGPT level was decreased in a dose dependent manner whereas in group 5 and 6 SGPT level declined is considered as statistically significant ( $p < 0.05$ ) when compared to diseased group 2. That means our plant can impart significant hepatoprotective activity.

### **3.1.2 SGOT**

Here in case of SGOT test group 4,5 and 6 SGOT level was decreased in a dose dependent manner whereas in group 5 and 6 SGPT level declined is considered as statistically significant ( $p < 0.05$ ) when compared to diseased control group. That means our plant can give significant hepatoprotective activity.

## **3.2 Kidney function test**

### **3.2.1 Creatinine Level Analysis**

The analysis of creatinine levels revealed a significant decrease ( $p < 0.05$ ) in both low and medium doses when compared to the diseased control group. This suggests that administration of these doses resulted in a notable decrease in creatinine levels. The increase in creatinine, a marker often associated with kidney function, indicates that the low and medium dosages had a significant impact on creatinine levels, differentiating them from the control group with disease.

### **3.2.2 Urea Level Analysis**

In contrast, the analysis of urea levels showed no statistically significant effect across any of the dosages tested. This indicates that, regardless of the dosage administered, there were no meaningful changes in urea levels compared to the

diseased control group. Consequently, urea levels remained stable and unaffected by the dosage variations in this study.

### **3.3 Lipid profile test**

#### **3.3.1 Total Cholesterol Level Analysis**

When analyzing total cholesterol levels, it was observed that there was a significant decrease only at high dosages in group 6 compared to group 2. Specifically, while total cholesterol levels in group 2 remained relatively stable, high doses administered to group 6 resulted in a marked reduction in total cholesterol, demonstrating the effectiveness of the high dosage treatment in lowering cholesterol levels.

#### **3.3.2 HDL Level Analysis**

Regarding HDL (high-density lipoprotein) levels, a notable increase was observed only at high doses in group 6 when compared to the disease control group. HDL, often referred to as "good" cholesterol, showed significant improvement under high dosage treatment conditions in group 6, indicating a beneficial effect of the treatment on HDL levels in contrast to the disease control group, which did not show such improvements.

#### **3.3.3 LDL Level Analysis**

For LDL (low-density lipoprotein) levels, significant reductions were observed exclusively at high doses in group 6. This decrease in LDL levels was statistically significant when compared to those in the diseased group 2. This finding highlights the impact of high-dose treatment in effectively lowering LDL levels, which is crucial for managing cholesterol-related health risks.

#### **3.3.4 Triglyceride Level Analysis**

In the study, the examination of triglyceride levels did not reveal any dosage that produced statistically significant differences when compared to the group with the disease. This means that, regardless of the specific levels or amounts of triglycerides administered or observed, there was no clear evidence suggesting that these triglyceride levels had a meaningful impact on the outcomes for the diseased group. Consequently, the data indicates that triglyceride dosage, in this

context, did not have a significant effect on the disease-related measures or conditions being studied.

Similar findings have been observed in studies using plant extracts such as *Diplazium esculentum*, and *Tamarindus indica*. Further research could focus on isolating individual beneficial molecules, using advanced techniques like NMR and mass spectrometry, to develop novel therapeutic drugs for managing hepatoprotective activities.

## **Conclusion**

The study shows that *Bixa Orellana* has significant hepatoprotective effects, especially at medium and high doses, improving liver function markers and lipid profiles. It also positively impacts kidney function. These results highlight its potential as a natural liver-protective agent. Further research is needed to explore its mechanisms, long-term efficacy, and safety to confirm its potential as a treatment option [23-25].

## **Ethical Approval**

All experimental procedures adhered to the guidelines of the Institutional Animals Ethics Committee (IEAC).

## **Disclaimer (Artificial intelligence)**

### **Option 1:**

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc) and text-to-image generators have been used during writing or editing of manuscripts.

### **Option 2:**

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc have been used during writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

## References

1. Mokdad, A. A., Lopez, A. D., Shahrzad, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., & Naghavi, M. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Medicine*, 12(1). <https://doi.org/10.1186/s12916-014-0145-y>
2. Kaplowitz, N. (2002). *Drug-Induced Liver Disease*. CRC Press.
3. 1.Traverso N, Ricciarelli R, Nitti M, Marengo B, Furfaro AL, Pronzato MA, et al. Role of Glutathione in Cancer Progression and Chemoresistance. *Oxidative Medicine and Cellular Longevity* [Internet]. 2013;2013:1–10. Available from: <https://www.hindawi.com/journals/omcl/2013/972913/>
4. Franco, R., & Cidlowski, J. A. (2009). Apoptosis and glutathione: beyond an antioxidant. *Cell Death & Differentiation*, 16(10), 1303–1314. <https://doi.org/10.1038/cdd.2009.107>
5. Kerksick, C., & Willoughby, D. (2005). The Antioxidant Role of Glutathione and N-Acetyl-Cysteine Supplements and Exercise-Induced Oxidative Stress. *Journal of the International Society of Sports Nutrition*, 2(2). <https://doi.org/10.1186/1550-2783-2-2-38>
6. Kretzschmar, M. (1996). Regulation of hepatic glutathione metabolism and its role in hepatotoxicity. *Experimental and Toxicologic Pathology*, 48(5), 439–446. [https://doi.org/10.1016/s0940-2993\(96\)80054-6](https://doi.org/10.1016/s0940-2993(96)80054-6)
7. Juliana Aditi Baroi, Md. Rakib Hossian, Md. Mustafiz Chowdhury, Nur-Neasha Dolon, Fahmida Maliha, Abdullah, M., Navila Nawjesh Lima, Md. Rahmat Ullah, & Rafat Tahsin. (2023). An Assessment of Anti-hyperlipidemic Potentialities of Ethanolic Extract of *Hemidesmus indicus* in High Fat Induced Rat Model. *Asian Journal of Food Research and Nutrition*, 2(4), 323–330. <https://journalajfrn.com/index.php/AJFRN/article/view/55>

8. Yang, L., & Stöckigt, J. (2010). Trends for diverse production strategies of plant medicinal alkaloids. *Natural Product Reports*, 27(10), 1469. <https://doi.org/10.1039/c005378c>
9. Phytochemistry of Medicinal Plants. (n.d.). [Www.phytojournal.com](http://www.phytojournal.com). <https://www.phytojournal.com/vol1Issue6/26.html>
10. Navila Nawjesh Lima, Nur-Neasha Dolon, Fahmida Maliha, Md. Rahmat Ullah, Fairuz Humayra, Md. Mustafiz Chowdhury, Abdullah, M., Juliana Aditi Baroi, F. M. Sharifuzzaman Shohan, & Rafat Tashin. (2023). An Evaluation of Analgesic and Anti-Inflammatory Activity of *Ficus racemosa* in Rat Model. *South Asian Research Journal of Natural Products*, 6(3), 169–176. <https://journalsarjnp.com/index.php/SARJNP/article/view/122>
11. Isratul Jannat Mim, Farhana Yesmin Peya, Md. Mustafiz Chowdhury, Tasnimur Rahman Khan, Souvik Kumar Mandal, Fahmida Maliha, Alam, M., Rahman, T., & Rafat Tashin. (2023). An Evaluation of Anti-Diabetic Activity of Ethanolic Extract of *Asparagus racemosus* in Alloxan Induced Rat Model. *International Journal of Advances in Nephrology Research*, 60–68. <https://journalijanr.com/index.php/IJANR/article/view/44>
12. Parvez, M. K., Ahmed, S., Al-Dosari, M. S., Mazin, Arbab, A. H., Al-Rehaily, A. J., & Al-Oqail, M. M. (2021). Novel Anti-Hepatitis B Virus Activity of *Euphorbia schimperii* and Its Quercetin and Kaempferol Derivatives. *ACS Omega*, 6(43), 29100–29110. <https://doi.org/10.1021/acsomega.1c04320>
13. Al-Qarawi, A. A., Al-Damegh, M. A., & El-Mougy, S. A. (2003). Hepatoprotective Influence of *Adansonia digitata* Pulp. *Journal of Herbs, Spices & Medicinal Plants*, 10(3), 1–6. [https://doi.org/10.1300/j044v10n03\\_01](https://doi.org/10.1300/j044v10n03_01)
14. Dilek tepe, H. (2019). Qualitative Analysis of Alfalfa Seed Methanol Extract by GC-MS and Determination of Antioxidant Properties. *Celal Bayar Üniversitesi Fen Bilimleri Dergisi*, 175–180. <https://doi.org/10.18466/cbayarfbe.493017>
15. Coelho dos Santos, D., Silva Barboza, A. da, Ribeiro, J. S., Rodrigues Junior, S. A., Campos, Â. D., & Lund, R. G. (2022). *Bixa orellana* L. (Achiote, Annatto) as an antimicrobial agent: A scoping review of its efficiency and technological prospecting. *Journal of Ethnopharmacology*, 287, 114961. <https://doi.org/10.1016/j.jep.2021.114961>

16. Samuelsen, A. B. (2000). The traditional uses, chemical constituents and biological activities of *Plantago major* L. A review. *Journal of Ethnopharmacology*, 71(1-2), 1–21. [https://doi.org/10.1016/s0378-8741\(00\)00212-9](https://doi.org/10.1016/s0378-8741(00)00212-9)
17. Senthil Kumar Raju, Chandrasekar, S., Priyadharshini Vengadhajalopathy, Sundaram, R., Sangeetha Periyasamy, Thatchayani Chinnaraj, Sekar, P., & Kumar, S. (2023). Review on phytochemical composition and pharmacological activities of *Bixa orellana*. *Journal of Pharmaceutical and Biological Sciences*, 10(2), 57–67. <https://doi.org/10.18231/j.jpbs.2022.012>
18. da Silva, A. K. A., dos Santos, C. R., Carneiro, M. L. B., Joanitti, G. A., Luz, G. V. S., Rosa, S. S. R. F., Pinheiro, W. M., Rosa, M. F. F., Abreu, P. R. A., Fukuoka, F. M. G., & Tatmatsu-Rocha, J. C. (2023, January 1). *Bixa orellana* L. and its implications in human health: Perspectives and new trends (Atta-ur-Rahman, Ed.). ScienceDirect; Elsevier. <https://www.sciencedirect.com/science/article/abs/pii/B9780323912945000014>
19. Shahid-ul-Islam, Rather, L. J., & Mohammad, F. (2016). Phytochemistry, biological activities and potential of annatto in natural colorant production for industrial applications – A review. *Journal of Advanced Research*, 7(3), 499–514. <https://doi.org/10.1016/j.jare.2015.11.002>
20. Meharie, B. G., Amare, G. G., & Belayneh, Y. M. (2020). Evaluation of Hepatoprotective Activity of the Crude Extract and Solvent Fractions of *Clutia abyssinica* (Euphorbiaceae) Leaf Against CCl<sub>4</sub>-Induced Hepatotoxicity in Mice. *Journal of Experimental Pharmacology*, Volume 12, 137–150. <https://doi.org/10.2147/jep.s248677>
21. Sharma, J., Gairola, S., Gaur, R. D., & Painuli, R. M. (2012). The treatment of jaundice with medicinal plants in indigenous communities of the Sub-Himalayan region of Uttarakhand, India. *Journal of Ethnopharmacology*, 143(1), 262–291. <https://doi.org/10.1016/j.jep.2012.06.034>
22. Vulimiri, S. V., Pratt, M. M., Kulkarni, S., Beedanagari, S., & Mahadevan, B. (2017, January 1). Chapter 21 - Reproductive and Developmental Toxicity of Solvents and Gases (R. C. Gupta, Ed.). ScienceDirect; Academic Press. <https://www.sciencedirect.com/science/article/abs/pii/B9780128042397000214>
23. Subramaniam, S., Hedayathullah Khan, H. B., Elumalai, N., & Sudha Lakshmi, S. Y. (2015). Hepatoprotective effect of ethanolic extract of whole plant of *Andrographis*

paniculata against CCl<sub>4</sub>-induced hepatotoxicity in rats. *Comparative Clinical Pathology*, 24(5), 1245–1251. <https://doi.org/10.1007/s00580-015-2067-2>

24. Junejo, J. A., Gogoi, G., Islam, J., Rudrapal, M., Mondal, P., Hazarika, H., & Zaman, K. (2018). Exploration of antioxidant, antidiabetic and hepatoprotective activity of *Diplazium esculentum* - A wild edible plant from North Eastern India. *Future Journal of Pharmaceutical Sciences*, 4(1), 93–101. <https://doi.org/10.1016/j.fjps.2017.10.005>
25. Narendar Koyagura, V. Hemanth kumar, M.G Jamadar, Huilgol, S. V., Nayak, N., Yendigeri, S. M., & Shamsuddin, M. (2013). Antidiabetic and hepatoprotective activities of *Tamarindus indica* fruit pulp in alloxan induced diabetic rats. *International Journal of Pharmacology and Clinical Sciences*, 2(2).

UNDER PEER REVIEW